Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 259Cyclophosphamide 243Specimen Handling 198fludarabine 174Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 121Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82Gemcitabine 79fludarabine phosphate 78Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Radiation 56Fluorouracil 56Azacitidine 56durvalumab 54Radiosurgery 53Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Antibodies, Bispecific × 1 year × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡